KR20050056190A - 암의 치료에서의 방사선 요법과 함께 혈관 내피 성장 인자수용체의 억제제인 ｚｄ6474의 병행 치료 - Google Patents

암의 치료에서의 방사선 요법과 함께 혈관 내피 성장 인자수용체의 억제제인 ｚｄ6474의 병행 치료 Download PDF

Info

Publication number
KR20050056190A
KR20050056190A KR1020057002082A KR20057002082A KR20050056190A KR 20050056190 A KR20050056190 A KR 20050056190A KR 1020057002082 A KR1020057002082 A KR 1020057002082A KR 20057002082 A KR20057002082 A KR 20057002082A KR 20050056190 A KR20050056190 A KR 20050056190A
Authority
KR
South Korea
Prior art keywords
ionizing radiation
treatment
methoxy
mmol
ylmethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020057002082A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 로버트 웨지
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0218525A external-priority patent/GB0218525D0/en
Priority claimed from GB0307560A external-priority patent/GB0307560D0/en
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20050056190A publication Critical patent/KR20050056190A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020057002082A 2002-08-09 2003-08-05 암의 치료에서의 방사선 요법과 함께 혈관 내피 성장 인자수용체의 억제제인 ｚｄ6474의 병행 치료 Ceased KR20050056190A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0218525A GB0218525D0 (en) 2002-08-09 2002-08-09 Combination therapy
GB0218525.4 2002-08-09
GB0307560A GB0307560D0 (en) 2003-04-02 2003-04-02 Combination therapy
GB0307560.3 2003-04-02

Publications (1)

Publication Number Publication Date
KR20050056190A true KR20050056190A (ko) 2005-06-14

Family

ID=31716921

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057002082A Ceased KR20050056190A (ko) 2002-08-09 2003-08-05 암의 치료에서의 방사선 요법과 함께 혈관 내피 성장 인자수용체의 억제제인 ｚｄ6474의 병행 치료

Country Status (13)

Country Link
US (1) US20050222183A1 (https=)
EP (1) EP1534287A1 (https=)
JP (1) JP2006502132A (https=)
KR (1) KR20050056190A (https=)
CN (1) CN1313094C (https=)
AU (1) AU2003249000B2 (https=)
BR (1) BR0313116A (https=)
CA (1) CA2495487A1 (https=)
IL (1) IL166522A0 (https=)
MX (1) MXPA05001458A (https=)
NO (1) NO20050450L (https=)
NZ (1) NZ537753A (https=)
WO (1) WO2004014383A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ301689B6 (cs) 1999-11-05 2010-05-26 Astrazeneca Ab Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ES2267748T3 (es) 2000-04-07 2007-03-16 Astrazeneca Ab Compuestos de quinazolina.
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
JP4608215B2 (ja) * 2002-02-01 2011-01-12 アストラゼネカ アクチボラグ キナゾリン化合物
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
RU2350618C2 (ru) 2002-11-04 2009-03-27 Астразенека Аб ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
PT1592423E (pt) * 2003-02-13 2011-06-16 Astrazeneca Ab Terapia de combinação de zd6474 com 5-fu e/ou cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
EP1648465B1 (en) * 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
WO2007071958A2 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
JP4945133B2 (ja) * 2006-01-19 2012-06-06 富士フイルムＲｉファーマ株式会社 ４−フェノキシキナゾリン誘導体放射性化合物
EP2066353B1 (en) * 2006-09-29 2013-01-02 AstraZeneca AB Combination of zd6474 and bevacizumab for cancer therapy
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
WO2009118560A1 (en) * 2008-03-28 2009-10-01 Astrazeneca Ab Combination therapy 038
CN106317022A (zh) * 2015-06-25 2017-01-11 中美华世通生物医药科技（武汉）有限公司 化合物的制备方法和用途
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ301689B6 (cs) * 1999-11-05 2010-05-26 Astrazeneca Ab Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje

Also Published As

Publication number Publication date
JP2006502132A (ja) 2006-01-19
CN1313094C (zh) 2007-05-02
CN1674905A (zh) 2005-09-28
US20050222183A1 (en) 2005-10-06
AU2003249000A1 (en) 2004-02-25
MXPA05001458A (es) 2005-06-06
AU2003249000B2 (en) 2007-04-05
NO20050450L (no) 2005-05-02
BR0313116A (pt) 2005-07-05
NZ537753A (en) 2008-04-30
IL166522A0 (en) 2006-01-15
WO2004014383A1 (en) 2004-02-19
EP1534287A1 (en) 2005-06-01
CA2495487A1 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
JP5563950B2 (ja) 組合せ療法
KR20050056190A (ko) 암의 치료에서의 방사선 요법과 함께 혈관 내피 성장 인자수용체의 억제제인 ｚｄ6474의 병행 치료
KR100959607B1 (ko) Ｚｄ6474 및 탁산을 포함하는 조합 요법
KR20120093411A (ko) 백금 화합물 및 임의적으로 이온화 방사능과 조합된 퀴나졸린 유도체 ｚｄ6474의 혈관신생 및/또는 증가된 혈관 투과성 관련 질환 치료 용도
KR20070072543A (ko) Ｚｄ6474 및 이마티닙을 포함하는 병합법
ZA200508858B (en) Therapeutic agents comprising an anti-angiogenic agent in combination with an Src-inhibitor and their therapeutic use
KR20060033785A (ko) Ａｚｄ2171 및 ｚｄ1839를 포함하는 암 병행 요법
MXPA06010758A (es) Terapia de combinacion.
KR20060034287A (ko) 병용 요법
ES2364030T3 (es) Terapia de combinación de zd6474 con 5-fu y/o cpt-11.
HK1084032B (en) Combination therapy of zd6474 with 5-fu and/or cpt-11

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050204

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20071010

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20090113

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20090731

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20090113

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I